Vanderbilt registers Phase 2 toripalimab trial in esophageal cancer, backed by CoherusSep 25Weekly roundup, 2 itemsadalimumab-aqvhadalimumab-atto
Coherus Oncology files to sell up to $50 million in stock through Leerink PartnersAug 28FinancingCoherus Oncology, Inc.
Coherus reports Q2 2026 results, flags October data update for tagmokitugAug 5Quarterly updateCoherus Oncology, Inc.toripalimab-tpzi
Sign inSign in